Every 8-K that PepGen Inc. (PEPG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PEPG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PEPG filings page.
PepGen Inc. reported second-quarter 2026 results and updates on its myotonic dystrophy type 1 program. Cash, cash equivalents and marketable securities were $117.2 million as of June 30, 2026, which the company expects will fund operations into the fourth quarter of 2027. For the quarter, research and development expenses were $12.5 million and general and administrative expenses were $6.4 million. Net loss was $17.8 million, or $(0.26) per share, compared with a $23.1 million loss, or $(0.70) per share, a year earlier.
An independent Data and Safety Monitoring Board recommended advancing the Phase 2 FREEDOM2-DM1 multiple ascending dose trial of PGN-EDODM1 into the highest dose cohort of 12.5 mg/kg with no protocol changes, and dose escalation in the open-label extension from 5 mg/kg to 10 mg/kg. The 10 mg/kg cohort is fully enrolled, with 7 of 8 participants having completed dosing; data are expected in November. Results from the 12.5 mg/kg cohort are expected in the first half of 2027, and an update from the open-label extension is expected by early January.
PGN-EDODM1, which uses PepGen’s Enhanced Delivery Oligonucleotide platform to target the RNA mechanism underlying DM1, has U.S. Orphan Drug and Fast Track designations and Orphan Designation in the EU. It remains an investigational therapy, with no regulatory approvals to date.
PepGen Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026, where shareholders voted on director elections and auditor ratification. A quorum was reached, with 54,650,845 shares present or represented by proxy out of 69,169,215 shares entitled to vote.
Stockholders elected three Class I directors—Howard Mayer, M.D., Joshua Resnick, M.D., M.B.A., and Lisa Wyman, M.S.—to serve until the 2029 annual meeting. Each nominee received tens of millions of votes in favor, with additional broker non-votes recorded.
Stockholders also ratified the appointment of KPMG LLP as PepGen’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 54,556,255 votes for, 77,083 against, and 17,507 abstentions.
PepGen Inc. furnished an updated corporate presentation outlining clinical progress for its investigational DM1 therapy PGN-EDODM1 and its cash runway. The company highlights its EDO delivery platform, which has shown up to a 98-fold increase in nuclear uptake of oligonucleotides in preclinical models and high levels of splicing correction and myotonia improvement with multiple doses. Early clinical data from the single-ascending-dose study show dose-dependent splicing correction, with 83% of patients at 15 mg/kg achieving more than 20% splicing improvement at Day 28 and robust muscle drug concentrations. Initial multiple-ascending-dose data at 5 mg/kg in the FREEDOM2 trial indicate a favorable safety profile, mean splicing correction of 22.9% excluding one outlier, and promising functional trends, supporting ongoing 10 mg/kg and planned 12.5 mg/kg cohorts. The company states it has a strong cash runway into the second half of 2027 through the FREEDOM2 12.5 mg/kg readout.
PepGen Inc. reported first quarter 2026 results and development updates for its PGN-EDODM1 program in myotonic dystrophy type 1. The 5 mg/kg cohort of the FREEDOM2-DM1 multiple ascending dose trial showed favorable safety and promising biomarker data, and the 10 mg/kg cohort is fully enrolled with results expected in the second half of 2026.
The company held $132.3 million in cash, cash equivalents and marketable securities as of March 31, 2026, which it believes will fund operations into the second half of 2027. For the quarter, research and development expenses were $13.0 million and general and administrative expenses were $5.9 million, leading to a net loss of $17.8 million, or $(0.26) per share, compared with a net loss of $30.2 million in the prior-year period.
The U.S. FDA placed a partial clinical hold on the FREEDOM2 study related to preclinical pharmacology and toxicology questions; PepGen states the trial’s timing has not been impacted and it is working with the agency to address these questions.
PepGen Inc. reported topline results from the 5 mg/kg multiple-ascending-dose cohort of its Phase 2 FREEDOM2-DM1 trial of PGN-EDODM1 in myotonic dystrophy type 1. PGN-EDODM1 was generally well-tolerated, with all treatment-emergent adverse events mild or moderate, no serious adverse events and no kidney-related events or cumulative toxicity.
Patients treated at 5 mg/kg showed a mean splicing correction of 7.3% versus 6.8% on placebo; excluding one outlier, mean splicing correction reached 22.9%. Middle-finger vHOT results showed promising trends at this lowest dose, though no meaningful benefit appeared in 10-meter walk/run or handgrip strength. Mean muscle tissue concentration was 158 ng/g one week after the fourth dose.
The 10 mg/kg cohort in FREEDOM2 is more than halfway enrolled, with data expected in the second half of 2026. PepGen has 12 patients in the 5 mg/kg open-label extension and expects its cash runway to extend into the second half of 2027. PGN-EDODM1 holds Orphan Drug and Fast Track designations in the U.S. and Orphan designation in Europe.
PepGen Inc. updated its corporate presentation to spotlight PGN-EDODM1, an investigational therapy for myotonic dystrophy type 1 (DM1) built on its EDO oligonucleotide delivery platform. The company reports dose-dependent, single-dose splicing correction in a Phase 1 study, with mean improvements of 12.3% at 5 mg/kg, 29.1% at 10 mg/kg, and 53.7% at 15 mg/kg, alongside generally well-tolerated safety with mainly mild to moderate adverse events. A multinational Phase 2 multiple-ascending-dose FREEDOM2-DM1 trial is under way, though a partial clinical hold has recently been placed by the U.S. FDA. PepGen highlights upcoming clinical readouts in Q1 2026 for the 5 mg/kg cohort and in the second half of 2026 for the 10 mg/kg cohort, and states it has cash runway into the second half of 2027.
PepGen Inc. reported 2025 results showing a net loss of $89.7 million, or $(2.12) per share, on operating expenses of $93.6 million. Cash, cash equivalents and marketable securities were $148.5 million as of December 31, 2025, which the company believes will fund operations into the second half of 2027.
The company highlighted Phase 1 data for PGN-EDODM1 in DM1, with mean splicing correction of 12.3%, 29.1% and 53.7% at 5, 10 and 15 mg/kg, and generally well-tolerated safety. At the same time, the FDA placed a partial clinical hold on the U.S. Phase 2 FREEDOM2-DM1 trial related to preclinical pharmacology and toxicology, while dosing at 10 mg/kg continues in Canada and the UK and regulatory clearances have been obtained in South Korea, Australia and New Zealand.
PepGen Inc. reported that on December 8, 2025 it appointed Joseph Vittiglio, Esq. as its Chief Business and Legal Officer. This new executive role combines responsibility for the company's business functions with oversight of legal affairs, adding depth to its leadership team. The company also furnished a related press release as Exhibit 99.1 providing additional detail on the appointment.
PepGen Inc. (PEPG) reported it furnished a press release announcing financial results for the quarter ended September 30, 2025. The company disclosed this under Item 2.02 (Results of Operations and Financial Condition), noting the release is provided as Exhibit 99.1.
The exhibit is furnished, not filed, which affects how it is incorporated by reference. PepGen’s common stock trades on the Nasdaq Global Select Market under the symbol PEPG. The 8-K was signed by CFO Noel Donnelly.
PepGen Inc. approved a company‑wide repricing of underwater employee stock options, effective November 4, 2025. Eligible options under the 2020, 2022 and 2024 plans now carry a new exercise price of $4.53. To use the reduced price, employees must remain in service through a defined retention period that ends on the earliest of March 31, 2027 or a qualifying sale event under the applicable plan.
The repricing covers 3,557,903 option shares that previously had exercise prices ranging from $8.89 to $17.91. The Board approved the change on the recommendation of the Compensation Committee; CEO James McArthur recused himself from the vote as an interested director. The company states the goal is to retain and motivate employees during a critical stage, noting that approximately two‑thirds of employee options were underwater at approval.
PepGen Inc. furnished an updated corporate presentation as of October 1, 2025. The company submitted the revised presentation as Exhibit 99.1 under a Regulation FD disclosure, meaning it is being provided for informational purposes and is not treated as filed financial reporting. The presentation is incorporated by reference only if specifically cited in future documents and the company notes that its inclusion does not, by itself, indicate that the information is material.
PepGen, Inc. (PEPG) disclosed an underwritten offering and related materials intended to fund its clinical programs and general corporate needs. The company says proceeds are expected to support the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials and for working capital and other general corporate purposes. The filing references an initial registration statement filed June 28, 2024 and declared effective July 8, 2024. The company expects the offering to close on or about September 26, 2025, subject to customary closing conditions. Listed exhibits include an Underwriting Agreement dated September 24, 2025, legal opinion and consent from Goodwin Procter LLP, launch and pricing press releases dated September 24, 2025, and an Inline XBRL cover page. The form is signed by CFO Noel Donnelly on September 26, 2025.
PepGen Inc. furnished an update on its DM1 program through a press release and an investor presentation. The company reported in the press release that it achieved what it describes as the highest mean splicing correction ever reported in patients with myotonic dystrophy type 1 (DM1). In addition, PepGen filed an updated presentation titled “Freedom-DM1, 15 mg/gk Cohort Data Update,” which its representatives plan to use in meetings with investors. The press release is provided as Exhibit 99.1 and the data update presentation as Exhibit 99.2.